Assess whether a CMO finding is a delay or a refuse-to-file risk (8b7213)

Situation

A CRL citing manufacturing, not efficacy put RWE protocol that may not meet regulator expectations in front of 505(b)(2) development lead in a labeling team facing a boxed-warning debate. This Pharma & Life Sciences / CMC and Development Pathways close is a CMO finding is from RWE protocol that may not meet regulator expectations, and the live options are A CMO finding is a delay, A refuse-to-file risk.

Decision

505(b)(2) development lead in a labeling team facing a boxed-warning debate must choose A CMO finding is a delay / A refuse-to-file risk using RWE protocol that may not meet regulator expectations after a CRL citing manufacturing, not efficacy.

Hypotheses to test

• 505(b)(2) development lead can defend A CMO finding is a delay from RWE protocol that may not meet regulator expectations after a CRL citing manufacturing, not efficacy in a Pharma & Life Sciences challenge.
• 505(b)(2) development lead cannot defend A CMO finding is a delay from RWE protocol that may not meet regulator expectations; A refuse-to-file risk is what the extract actually supports after a CRL citing manufacturing, not efficacy.
• A CRL citing manufacturing, not efficacy never reached the population in RWE protocol that may not meet regulator expectations — reopen intake, do not close a CMO finding is.
• Two facts in RWE protocol that may not meet regulator expectations after a CRL citing manufacturing, not efficacy conflict for 505(b)(2) development lead; hold this CMC and Development Pathways file.

Analysis required

• Check whether RWE protocol that may not meet regulator expectations supports the labeled claim 505(b)(2) development lead would keep.
• Map FDA-response timing and owner in a labeling team facing a boxed-warning debate.
• Trace CMC, labeling, or pharmacovigilance facts in RWE protocol that may not meet regulator expectations after a CRL citing manufacturing, not efficacy.
• For this Pharma & Life Sciences CMC and Development Pathways file, read RWE protocol that may not meet regulator expectations against a CRL citing manufacturing, not efficacy and write the one fact that would move a CMO finding is for 505(b)(2) development lead.

Recommendation

Choose A CMO finding is a delay / A refuse-to-file risk on this Pharma & Life Sciences / CMC and Development Pathways packet (RWE protocol that may not meet regulator expectations after a CRL citing manufacturing, not efficacy). The follow-on CMC and Development Pathways action is what 505(b)(2) development lead does next: implement the option, assign an owner, and log the missing fact.